CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002
In connection with this Quarterly Report of VitaSpring Biomedical Co., Ltd. (the “Company”), on Form 10-Q for the period ended July 31, 2021, as filed with the U.S. Securities and Exchange Commission on the date hereof, I, Kao Cheng-Hsiang, Principal Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | Such Quarterly Report on Form 10-Q for the period ended July 31, 2021, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in such Quarterly Report on Form 10-Q for the period ended July 31, 2021, fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: September 15, 2021 | By: | /s/ Kao, Cheng-Hsiang |
| Kao, Cheng-Hsiang | ||
Principal Financial Officer VitaSpring Biomedical Co., Ltd. |
